For the myotwin team, the convention was more than just an industry gathering – it was a valuable opportunity to present its technology platform for the development of new cardiovascular therapeutics on an international stage and to further expand its network. The focus was on intensive discussions with potential partners from pharma and biotech – both at the booth and in the partnering sessions, which provided important impulses for upcoming collaborations.
The participation was supported by the Federal Ministry for Economic Affairs and Energy (BMWE), BIO.NRW, and NRW.Global Business. In particular, the shared booth as part of the NRW pavilion proved to be of great value for myotwin’s presence at the convention. The company extends its sincere thanks for this support, which further strengthened its visibility on the international stage.
After numerous discussions, new contacts, and initial approaches to partnerships, myotwin draws a thoroughly positive conclusion from BIO 2025. The convention once again confirmed its importance as a platform to showcase innovation and to initiate the next phase of growth together with strong partners.
About myotwin
myotwin is a biotech company specializing in human–relevant, preclinical testing systems for the development of cardiovascular drugs. With its proprietary myoScreen platform, myotwin enables the simultaneous measurement of contraction force, tissue stiffness, calcium dynamics, and electrical activity—directly on human heart tissue.
As a next step, myotwin is developing myoAI, a digital twin of the heart muscle that uses artificial intelligence to predict the efficacy and toxicity of drugs. This is giving rise to a new generation of precise, data-driven drug development.
The Germany-based company works closely with research institutions, industry partners, and investors to advance innovative therapies for cardiovascular diseases more quickly and in a more targeted manner. For more information, visit www.myotwin.com.
Forward–looking statements
This communication may contain forward–looking statements based on current assumptions and forecasts made by myotwin’s management. Various known and unknown risks, uncertainties, and other factors could cause the actual results, financial position, development, or performance of the company to differ materially from the estimates given here. These factors include those described in myotwin’s public reports, which are available on the myotwin website at www.myotwin.com. The company assumes no obligation to update such forward-looking statements or to adapt them to future events or developments.
